Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 66
Inquire Before Buying

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2018, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline landscape.

MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms include abnormal bones in the spine, claw hand, cloudy corneas, deafness and heart valve problems. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 1, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Overview
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Companies Involved in Therapeutics Development
AngioChem Inc
ArmaGen Inc
CRISPR Therapeutics
Eloxx Pharmaceuticals Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
OPKO Health Inc
RegenxBio Inc
Sangamo Therapeutics Inc
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Drug Profiles
AGT-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide for Mucopolysaccharidosis I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate IDUA for Mucopolysaccharidosis I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELX-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JOT-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
laronidase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGTA-456 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Alpha-L-Iduronidase Replacement for Mucopolysaccharidosis I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RGX-111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-318 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Alpha L-Iduronidase for Type1 Mucopolysaccharidosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Target Alpha L-Iduronidase for Hurler Sydrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tamid-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-372 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Dormant Projects
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Discontinued Products
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Product Development Milestones
Featured News & Press Releases
May 02, 2018: Immusoft Granted Orphan Drug Designation for Treatment of Rare Childhood Disease
Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
Mar 14, 2018: Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I
Feb 08, 2018: ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I
Feb 05, 2018: Jupiter Orphan Therapeutics in Process to Submit IND for MPSI and Other Indications
Dec 08, 2017: Sangamo Announces EMA Recommendation of Orphan Medicinal Product Designation for Investigational Genome Editing Treatment for Mucopolysaccharidosis Type I
Nov 30, 2017: ArmaGen's AGT-181 Granted Fast Track Designation for the Treatment of Hurler Syndrome (MPS I)
Oct 26, 2017: JCR to Initiate Development of JR-171, a New Drug Candidate for Hurler Syndrome Using J-Brain Cargo
Aug 08, 2017: REGENXBIO Announces IND Active for Phase I Trial of RGX-111 to Treat Mucopolysaccharidosis Type I
Jul 13, 2017: Sangamo Receives Fast Track Designation From The FDA For SB-318 In Vivo Genome Editing Product Candidate For The Treatment Of MPS I
Feb 27, 2017: Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I
Feb 16, 2017: ArmaGen Reports Preliminary Evidence of Cognitive Improvement in Children with Hurler Syndrome (MPS I) Treated with AGT-181
Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-318 at The 13th Annual WORLDSymposium Meeting
Feb 07, 2017: ArmaGen Announces Oral Presentation of Preliminary Results from its Phase 2 Clinical Trial of AGT-181 in Patients with MPS 1 to be Presented at WORLDSymposium 2017
Jan 11, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by AngioChem Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by ArmaGen Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by CRISPR Therapeutics, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Eloxx Pharmaceuticals Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Immusoft Corp, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by OPKO Health Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by RegenxBio Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline by Sangamo Therapeutics Inc, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Dormant Projects, H1 2018
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Addiction Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 135
    Drug addiction is a chronic, recurrent disease characterized by the uncontrolled application of an addictive drug. In recent years, the abuse of exogenous opioids (such as morphine and heroin) has become a serious social problem. It does not care about the physical and mental health of the abuser himself. It also has disastrous consequences for families and society. Opioid withdrawal is extremely difficult once it is abused. Scope of the Report: This report focuses ......
  • Global Turmeric Capsules Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 137
    The aromatic root of the turmeric plant has been used for centuries as a treatment for digestive disorders, inflammation, arthritis and infection. Many of turmeric's historic uses are not necessarily supported by scientific evidence. Nevertheless, turmeric supplements are commonly prescribed as a component of modern integrative medicine. early studies suggest that turmeric can promote the health of your joints, blood vessels and digestive tract. Compounds in turmeric capsules may also offer hope......
  • Global Alpha 1 Antitrypsin Deficiency Treatment Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 150
    Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma. Scope of the Report: This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.......
  • Global Alpha Mannosidosis Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 113
    Alpha-mannosidosis is a lifelong multi-systemic progressive disease, with neuromuscular and skeletal deterioration over decades. Scope of the Report: This report focuses on the Alpha Mannosidosis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. There is no cure for congenital alpha-mannosidosis, and in......
  • Global Ambulatory Surgical & Emergency Center Services Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 128
    The Modern Ambulatory Surgical & Emergency Center Services has developed into a large-scale emergency medical technology center and emergency medical science research center integrating treatment and rescue, medical referral, technical guidance and emergency treatment, emergency and intensive care, and can be used for emergency, critical, and critical patients. The implementation of one-stop emergency medical services without transfer was described as the symbol of modern medicine and the patron......
  • Global Anesthesia Gas Blender Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 137
    The anesthesia machine is complex in structure and consists of a gas source, a gas mixing system, an anesthetic gas evaporator, a breathing circuit, a ventilator, an exhaust system, a monitoring system, an information management system, etc., and the user's safety, accuracy, reliability and Ease of use is higher. After more than half a century of development, the function of the anesthesia machine has basically not changed. The development of the gas supply system, the mechanical gas mixing syst......
  • Global Animal Blood Plasma Products and Derivatives Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 130
    Animal blood is one of the main by-products of animal slaughtering and processing. It has rich protein content and high nutritional value. Plasma protein, as an important protein material, can be used for animal feed and food processing. Studies have shown that plasma proteins are enzymatically treated to obtain hydrolysates consisting of small peptides and amino acids, which are more easily digested and absorbed by the body. At the same time, they show antioxidant properties, inhibition of angi......
  • Global Animal Health Care Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 135
    By 2050, the global population will expand to 9 billion - a two-thirds increase in future animal protein consumption. Population and income growth will bring about an increase in the consumption of animal protein. The growing demand for protein has given producers an opportunity to improve their production and profitability. Jianming's "all-round nutrition" solution meets two basic needs: providing healthy and safe nutrition solutions and maintaining good economic benefits. Scope ......
  • Global Anticancer Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 23-Oct-2018        Price: US 3480 Onwards        Pages: 129
    Antineoplastic drugs, also known as anticancer drugs, anti-malignant drugs, refer to drugs for the treatment of malignant tumors. Scope of the Report: This report focuses on the Anticancer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Simply put, there are chemotherapy drugs and biological age......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs